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ABSTRACT An agonist-initiated Ca21 signaling model for calmodulin (CaM) coupled to the phosphorylation of myosin light
chains was created using a computer-assisted simulation environment. Calmodulin buffering was introduced as a module for
directing sequestered CaM to myosin light chain kinase (MLCK) through Ca21-dependent release from a buffering protein.
Using differing simulation conditions, it was discovered that CaM buffering allowed transient production of more Ca21-CaM-
MLCK complex, resulting in elevated myosin light chain phosphorylation compared to nonbuffered control. Second messenger
signaling also impacts myosin light chain phosphorylation through the regulation of myosin light chain phosphatase (MLCP). A
model for MLCP regulation via its regulatory MYPT1 subunit and interaction of the CPI-17 inhibitor protein was assembled that
incorporated several protein kinase subsystems including Rho-kinase, protein kinase C (PKC), and constitutive MYPT1
phosphorylation activities. The effects of the different routes of MLCP regulation depend upon the relative concentrations of
MLCP compared to CPI-17, and the speciﬁc activities of protein kinases such as Rho and PKC. Phosphorylated CPI-17 (CPI-
17P) was found to dynamically control activity during agonist stimulation, with the assumption that inhibition by CPI-17P
(resulting from PKC activation) is faster than agonist-induced phosphorylation of MYPT1. Simulation results are in accord with
literature measurements of MLCP and CPI-17 phosphorylation states during agonist stimulation, validating the predictive
capabilities of the system.
INTRODUCTION
The construction of models that can be used for simulation of
biological systems provides a means to formulate new hy-
potheses about the system and then test these hypotheses ex-
perimentally. However, the complexity of biological systems
and the differences in experimental starting points make it
difﬁcult to establish a standard formula for modeling a given
system. Although several mathematical suites and simulation
environments are available, few provide a simple interface to
mathematical algorithms and differential equation solvers that
are necessary to provide understandable graphical and
numerical output for the cell biologist or biochemist. To this
end, the Virtual Cell provides a common, user-operable
interface for designing and launching biochemical simula-
tions (Loew and Schaff, 2001; Slepchenko et al., 2003).
Models of Ca21 mobilization in neurons (Slepchenko et al.,
2002; Fink et al., 2000) and smooth muscle cells (Fink et al.,
1999) provide the framework for building more extensive
models capable of simulating the entire pathway from agonist
to cellular endpoint. One of the ubiquitous cellular signaling
pathways involves mobilization of Ca21 and activation of
calmodulin (CaM) targeted enzymes. In a previous report,
a model of agonist-mediated Ca21 mobilization coupled to
Ca21-CaM signaling in smooth muscle cells was created and
validated with respect to agonist sensitivity and Ca21-
mediated CaM activation of a downstream protein kinase
(Lukas, 2004). With this model, it is now possible to explore
additional features of the Ca21 signaling pathway including
the questions of calmodulin buffering and details of the
regulation of a biochemical system. The CaM-myosin light
chain kinase (MLCK) system and its associated regulatory
elements are the focus of this report. The strategies used
for integrating multiple kinase and phosphatase regulatory
systems are outlined, as well as the concept of speciﬁc CaM
buffering, a process for delivering CaM to a subset of Ca21-
dependent processes.
Using simulation data to predict CaM-buffer properties,
myosin Ic was implicated as a CaM buffering protein
associated with the smooth muscle cytoskeleton. One of the
three CaM-binding IQ domain motifs of Myosin Ic was
identiﬁed as a CaM buffering domain based upon the mea-
sured CaM-binding properties of a synthetic peptide analog.
Simulation data suggest that the Ca21-independent binding
and release of CaM by myosin Ic delivers CaM to the
ﬁlament-bound MLCK, thus providing a conduit for
activation of myosin-based contraction. Details of the
regulation of myosin phosphatase activity were also eluci-
dated by simulation data. An estimate of the level of phos-
phorylated MYPT1 subunit was obtained by running
simulations with various levels of prephosphorylated subunit
and allowing additional phosphorylation during a typical
Ca21 transient. Similarly, the dynamic role of CPI-17
activated by phosphorylation in modulating myosin light
chain phosphatase (MLCP) activity was also elaborated by
comparing simulation output to existing experimental results.
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METHODS
Model building strategy
The modules built for regulation of the phosphorylation state of smooth
muscle myosin are shown in Fig. 1. Agonist-induced Ca21 generation and
sequestration were done as described (Lukas, 2004). In the prototype
system, the MLCK and MLCP concentrations are equal (10 mM), and the
levels of other regulatory molecules estimated from the literature (Table 1)
and optimized by simulation as needed. As outlined below, each step of the
process was compared by simulation to any existing data, and the model
parameters further reﬁned to achieve a close ﬁt. The system was also found
to be scalable to other types of cells that contain different amounts of
MLCK, MLCP, and calmodulin.
All simulations presented in this work used the Runge-Kutta fourth-order
solver with a ﬁxed time step of 0.1 ms. Ordinary differential equations
(ODE) were generated by the Virtual Cell suite (www.nrcam.uchc.edu). The
biomodel system (including the ODEs) can be exported to other simulation
programs by way of the export functions on the XML part of the Virtual Cell
model page. Thus, the simulation suite is designed to be portable and
available to a wide variety of researchers. The described Virtual Cell
biomodel can be found in the public directory Ca release-coupled myosin
light chain (MLC).
Calmodulin buffering
The total buffer concentration was 15 mM and a Kd of 10 mMwas assumed.
Thus, the model was built around a single class of CaM-buffering proteins
that could sequester CaM proximal to other CaM targets (such as MLCK)
and then liberate CaM during a Ca21 ﬂux. Thus, CaM delivery to MLCK
was derived using Eqs. 1–3:
CaM1Buffer 4 CaM-Buffer complex: (1)
CaM-Buffer-complex1 2Ca214CaM-Ca21ð2Þ
1 2Ca21/CaM-Ca21ð4Þ : (2)
CaM-Ca
21
ð4Þ 1MLCK4CaM-Ca
21
ð4Þ -MLCK: (3)
The scheme assumes that 2 mol of Ca21 are needed to dissociate CaM from
the buffer complex and that this transient CaM with two bound Ca21 rapidly
acquires two more Ca21 and then binds to and activates MLCK. The kinetic
constants for these steps were further reﬁned by simulations (see Results).
Regulation of myosin light chain phosphatase
The Km and speciﬁc activity values for the constitutive and RhoA stimulated
activity (Table 1) were used to parameterize MYTP1 phosphorylation.
StimulatedMYTP1 phosphorylationwas coupled to the production of RhoA.
Activated RhoA (GTP-bound) is generated by exchange from G11/12 species,
coupled to a subpopulation of agonist receptors (Somlyo and Somlyo, 2000).
This process is catalyzed by RhoA exchange factors (RhoGEFS) (Blomquist
et al., 2000), but reaction kinetics or binding parameters are not available for
these species. Therefore, RhoA generation was set up in a hypothetical
manner by exchanging a portion of the activated (GTP-bound) Gq to RhoA-
GTP. RhoA-GTP was allowed to inactivate through hydrolysis of its bound
GTP at a basal rate of 0.1/s. The second regulatory mechanism for MLCP
involves inhibition through the small protein inhibitor CPI-17. CPI-17
phosphorylated at Thr-38 binds to MLCP with a Kd of 1–5 nM and inhibits
activity (Hayashi et al., 2001; Kitazawa et al., 2000). Experimental data
suggest that diacylglycerol (DAG)-activated PKC (a and g) phosphorylate
CPI-17 in smooth muscle cells (Kitazawa et al., 2003), tissues (Woodsome
et al., 2001; Ogut and Brozovich, 2000), and in some nonmuscle cells such as
platelets (Watanabe et al., 2001). Thus, CPI-17 phosphorylation was coupled
to DAG production and PKC activation using enzyme explicit Michaelis
parameters and a PKC concentration of 1 mM (see Table 1). In the current
model, the concentration ofMLCPwas set equal toMLCK (10mM) and CPI-
17 was set at 6 mM near the upper limit estimated in smooth muscle cells
(Woodsome et al., 2001). The dephosphorylation of the CPI-17P-MLCP
complex and CPI-17P were formulated by irreversible Michaelis-Menton
kinetics with a kcat of 1/s and Km of 1 mM.
Countering the downregulation of MLCP, static levels of cGMP were
coupled to MLCP activation through a direct or indirect reversal of the
inhibitory Rho kinase-mediated phosphorylation (Surks et al., 1999; Sandu
et al., 2001). Although cG kinase (the target of cGMP) phosphorylates
MYPT1, it apparently does not alter MLCP activity (Nakamura et al., 1999).
The parameters for cG kinase-mediated reversal of MLCP inhibition were
based upon cGMP binding and activation of cG kinase with an EC50 for
cGMP of 0.57 mM (Smith et al., 2000). The cG-kinase concentration was
ﬁxed at 0.1 mM (Francis et al., 1988) and the concentration of cGMP was
ﬁxed at the estimated cGMP concentration (0.1 mM) in smooth muscle
(Smith et al., 2000; Francis et al., 1988). The phosphatase that is most
effective in dephosphorylating MYPT1 is PPA2c (Takizawa et al., 2002b);
however, a direct link between cG kinase and this phosphatase has not been
established. Thus, cG kinase-induced dephosphorylation of MYPT1 was
done in a hypothetical fashion ‘‘catalyzed’’ by cG kinase.
Binding of CaM to IQ-domain peptides
Dansyl bovine brain calmodulin (Dansyl-CaM) was prepared as described
(Vorherr et al., 1990). The stoichiometry was 0.9–1.2 mol/mol and the
ﬂuorescent protein used at a concentration of 200 nM. Synthetic peptides
based upon myosin Ic IQ domains, IQ1 ¼ RKHSIATFLQARWR-
GYHQRQKFL and IQ2 ¼ HMKHSAVEIQSWWRGTIGRRKAA, were
prepared by standard solid-phase methods using Fmoc-protected amino
acids as described previously (Lukas et al., 1999). Peptides were puriﬁed by
reverse-phase high-performance liquid chromatography on a Phenomenex
C5 column. Puriﬁed peptides gave the expected MH1 ions (IQ1 ¼ 2928.6,
FIGURE 1 Downstream signaling elements in the cytoplasmic compart-
ment. Shown are the details of the MLC phosphorylation/dephosphorylation
module. The simulation system contains dynamic regulation of MLCK
activity through Ca21-CaM and MLCP activity through phosphorylation by
Rho kinase and inhibition by phosphorylated CPI-17. CPI-17 is phosphor-
ylated by PKC that is activated by DAG produced by activated
phospholipase C. RhoA that is generated by G-protein exchange with
receptor activated G proteins activates Rho kinase, and cG kinase is
activated by cGMP.
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calc ¼ 2928.4; IQ2 ¼ 2706.1, calc ¼ 2706.2) in matrix-assisted laser
desorption ionization time-of-ﬂight mass spectra.
Peptide binding was done in 25 mM Tris, 1 mM EDTA, 150 mM NaCl,
pH 7.5). Solutions of Dansyl-CaM in the binding buffer were placed into
a 96-well microtiter plate (Falcon). Peptide was then added to the desired
ﬁnal concentration from a concentrated stock solution in water. Total
volume remained constant at 110 mL. Fluorescence was read in a Victor 2
spectrometer using 335-nm excitation and 535-nm emission ﬁlters. The data
were corrected for background ﬂuorescence and expressed as the ratio F/Fo,
where Fo is the ﬂuorescence of Dansyl-CaM in the absence of peptide and F
is the measured ﬂuorescence in the presence of increasing concentration of
peptide. Data were ﬁt to Eq. 4 to obtain the binding constant, K:
K=ð1 aÞ ¼ ð½Peptide=aÞ  ½Dansyl-CaM; (4)
where a¼ F Fo/FN Fo and FN is the calculated endpoint ﬂuorescence
value. The binding constant K equals the reciprocal slope of a plot of 1/1 a
versus [Peptide]/a (Vorherr et al., 1990).
RESULTS
The details of the regulatory model for myosin light chain
phosphorylation are illustrated in Fig. 1. The importance of
each of the subsystems involved in the regulation of the
maximal amount of Ca21 -CaM-MLCK complex will be
evaluated using simulations based upon the model and
compared to existing results.
Properties of CaM buffering proteins
The level of free CaM in the cytoplasm under resting
conditions has been estimated at 0.25–1 mM using various
techniques (Zimmermann et al., 1995; Tran et al., 2003). The
total amount of CaM, however, is on the order of 20–50 mM
(Zimmermann et al., 1995; Tran et al., 2003). Thus, without
release from CaM-buffering proteins, the activation of CaM
targets through increases in Ca21 is apparently limited by the
free CaM concentration. However, certain CaM targets that
bind CaM (at low Ca21) provide a source of CaM that is
released to activate targets during aCa21 ﬂux. Although some
CaM remains associated with isolated actomyosin cytoskel-
etons (Wilson et al., 2002), it is not clear how much CaM is
actually bound to MLCK compared to other CaM binding
proteins. In the formulation of the model for smooth muscle,
10 mM MLCK and 1 mM free CaM at equilibrium provided
0.36 mM CaM associated with MLCK under resting con-
ditions. Under these conditions, simulations predicted that
the activated MLCK would yield only ;28% of the peak
phosphorylated MLC (0.6 mol/mol) observed in agonist-
stimulated smooth muscle cells (Wilson et al., 2002; Taylor
andStull, 1988), suggesting thatMLCKalone does not appear
to sequester enough CaM at resting Ca21 to provide a
physiological level of MLC phosphorylation in smooth
muscle. The concentration of a hypothetical CaM-buffer pro-
tein was adjusted to buffer 3 mM CaM, similar to that esti-
mated in smooth muscle cytoskeleton (Wilson et al., 2002).
Fig. 2 A illustrates the effect of changing the Ca21
dissociation constant of a CaM-buffer protein complex
over the 1–20 mM range assuming that the buffer pro-
tein dissociates CaM upon binding Ca21. Compared with the
MLC phosphorylation activity obtained in the absence of
buffering, it appears that in this system, the Ca21 dissociation
constant for a CaM-buffer protein should be less than 5 mM
to enhance phosphorylationmore than twofold. Surveying the
known CaM-binding proteins associated with the cytoskel-
eton, a plausible CaM buffering protein is myosin Ic
(Coluccio, 1997). Myosin Ic contains three potential CaM-
binding IQ motifs that occur in tandem (Coluccio, 1997;
Gillespie and Cyr, 2002). Experiments done in vitro have
demonstrated that 1 mol/mol of CaM is released by myosin Ic
at elevated Ca21 concentrations (Collins et al., 1990),
supporting its potential role as a CaM buffer. Recent studies
of synthetic peptide analogs of the IQ domains of myosin Ic
indicated that two IQ domain peptide analogs ﬁt the require-
ment of being able to bind CaM in the absence of Ca21 and
weakly in the presence of Ca21 (Gillespie and Cyr, 2002).
Using the published data on CaM binding to the peptide
analogs and assuming that binding of at least two calcium ions
causes CaM to dissociate from the complex (Zhu et al., 1998),
the calculated Ca21 sensitivity of the dissociation of CaM
from these IQ domains is in the range of 2–4mM, comparable
with the values obtained from the simulations. As shown in
Fig. 2B, the difference in the peak ofMLC phosphorylation is
at least threefold greater with CaM buffering than in its
TABLE 1 Ca21, CaM, MLCK, PKC, and MLCP kinetic parameters
Reaction Kd (mM) kforward M
1 s1 References
Ca21-CaM 1 MLCK4 Ca21-CaM-MLCK 0.0011 28 (Johnson et al., 1996; Kasturi et al., 1993)
Ca21-CaM 1 MLCK-P4 Ca21-CaM-MLCK-P 0.023 8 (Johnson et al., 1996; Kasturi et al., 1993)
CaM 1 BufferP4 CaM-BufferP 5 5 See text
CaM-BufferP 1 2Ca214 Ca21-CaM 1 BufferP 2.5 75 See text
MLCP 1 CPI-17P4 MLCP-CPI-17P 0.005 5 (Feng et al., 1999b), see text
Enzyme kinetics Km mM kcat s1
Rho Kinase 1 MYPT/ MYPT-P (MLCP-P) 2.5 2.5 (Feng et al., 1999b)
RhoA-Rho Kinase 1 MYPT/ MYPT-P (MLCP-P) 2.5 1.5 (Feng et al., 1999b)
PKC 1 CPI-17/ CPI-17P 1.0 4.0 (Senba et al., 1999), see text
CPI-17P (dephosphorylation)/ CPI-17 1.0 1.5 See text
MYPT-P 1 (cG kinase-activated)/ MYPT 1.0 1.0 See text
Values were optimized by comparison to experimental data.
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absence and the level of activated Ca21-CaM-MLCK
complex increases proportionately (Fig. 2 B, inset) Thus,
based upon these results, myosin Ic is predicted to be a CaM
buffer for MLCK activation in smooth muscle.
To determine which IQ domain peptide analog of myosin
Ic was a more representative CaM-buffering domain
required reinvestigation of their CaM binding properties.
Fig. 3 shows that one peptide analog (IQ1) binds well to
Dansyl-CaM (Kd ¼ 2 mM) in the presence of 1 mM Ca21
chelator, whereas the other peptide analog from the adjacent
IQ domain (IQ2) of myosin Ic has weaker afﬁnity for CaM
(Kd . 20 mM). The IQ1 peptide (up to 40 mM) does not
change the ﬂuorescence of Dansyl-CaM in the presence of
1 mM Ca21, suggesting that it only weakly interacts with
the Ca21-bound form of CaM (data not shown).
Simulations forecast the effects of changing
MLCP regulatory elements
Inhibition of MLCP is mediated through phosphorylation of
one or more sites in the MYPT regulatory subunit (Thr 695
and/or Thr-850) (Feng et al., 1999a; Kawano et al., 1999)-
human MYPT numbering. Several kinases phosphorylate
MYPT in vitro, including Rho kinase (Feng et al., 1999a;
Kawano et al., 1999), p21-activated kinase (PAK) (Takizawa
et al., 2002a), integrin-linked kinase (Kiss et al., 2002), and
Raf-1 (Broustas et al., 2002). Phosphorylation at Thr-695
of MYPT decreases MLCP activity (Borman et al., 2002)
and sensitizes muscle tissue to contract at lower Ca21
(Somlyo and Somlyo, 2000). Studies with phosphorylation
site-directed antibodies indicate that MYPT1 phosphoryla-
tion state increases 1.5- to 4-fold upon agonist treatment
(Watanabe et al., 2001; Seko et al., 2003). Thus, a portion
of MYPT1 is phosphorylated in resting cells, but the ratio
of phosphorylated to unphosphorylated MYPT1 in resting
tissues is not known; therefore, this initial valuewas estimated
by the simulation process. Applying the known parameters
for enzymatic activities (Table 1), simulation data indicates
that the level of MLCP activity limits the maximal MLC
phosphorylation realized by an agonist-stimulated Ca21
transient. As illustrated in Fig. 4 A, the initial level of
phosphorylated MYPT subunit of MLCP was varied. At the
peak, nearly all of theMLC is phosphorylated when the initial
stoichiometry of MYPT1 subunit phosphorylation is .0.5.
This level of activity is inconsistent with experiments in
smooth muscle tissues and cells whereMLC phosphorylation
peaks at ;60% of total (Taylor and Stull, 1988). Thus, the
initial level of phosphorylated MLCP was set at 0.25 (25%)
allowing for a further increase in phosphorylation state during
aCa21 transient, consistentwithprevious experimental results
(Kitazawa et al., 2003; Watanabe et al., 2001).
Depending upon the cell or tissue, one or both mecha-
nisms ofMLCP regulation (phosphorylation and inhibition by
CPI-17) dynamically decrease MLCP activity (Kitazawa
et al., 2003;Watanabeet al., 2001).How theseparametersvary
with agonist concentration under various conditions is not
clear because the endpoint measurement reﬂects the conver-
gence of multiple enzymatic processes that occur in different
time frames. The model was tested in simulations represent-
ing various conditions and the effects of inhibiting
FIGURE 3 Binding of myosin Ic IQ-domain peptide analogs to CaM.
Dansyl-bovine brain calmodulin (200 nM) was titrated with peptide IQ1,
RKHSIATFLQARWRGYHQRQKFL (squares) or IQ2, HMKHSA-
VEIQSWWRGTIGRRKAA (circles) in 50 mM Tris, 150 mM NaCl, 1
mM EDTA, pH 7.5. Error bars are from duplicates run in the titration assay.
Fluorescence emission was measured at 535 nm with excitation at 335 nm
(10-nm band pass) using a Victor 2 96-well plate reading ﬂuorometer. Data
are corrected for background ﬂuorescence in the absence of Dansyl-CaM.
FIGURE 2 Predicted effects of calmodulin buffering on peak MLC
phosphorylation and Ca21-CaM-MLCK complex formation. (A) Effect of
changing the Ca21 dissociation constant for the CaM-buffer protein
complex on the peak of MLC phosphorylation. (B) Proﬁle of MLC
phosphorylation (MLC_P) and Ca21-CaM-MLCK complex formation
(inset) in the presence (solid line) and absence (dotted line) of CaM
buffering. Simulations were run at a ﬁxed ligand (100-nM) concentration.
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CPI-17 phosphorylation, stimulated MLCP phosphorylation
(via Rho kinase), or both (Fig. 4 B). Inhibition of CPI-17 or
MLCP phosphorylation (enhancing MLCP activity) de-
creases the maximal MLC phosphorylation by .50%. The
shape of theMLCphosphorylation proﬁle ismultiphasic, with
both CPI-17 and MLCP phosphorylation contributing to the
overall response. The contribution of each towardmodulating
MLCP activity is dependent upon the agonist concentration.
CPI-17 phosphorylation parallels that of MLC phosphoryla-
tion at most ligand concentrations (Fig. 5). The simulated
results also predict that RhoA kinase-stimulated MLCP
phosphorylation is slow even at high agonist concentrations.
At low agonist concentrations, the time to MLC phosphor-
ylation peak is slower (;15 s) compared to higher agonist
concentrations (6–8 s) but the peak Ca21-CaM-MLCK
complex occurs between 3 and 6 s (Fig. 5). Thus, within this
time window the level of MLC phosphorylation achieved is
limited because the MLCP has not yet been inhibited by CPI-
17P. This is seen as an inﬂection on the MLC proﬁle at 3 s
(Fig. 5). At the lowest ligand concentration (1 nM), MLC
phosphorylation parallels CPI-17P-mediated inhibition, re-
sulting in a delayed peak response. These data suggest that
agonist-induced MLC phosphorylation state in some stimu-
lated cells or tissues may exhibit a rapid peak of MLC
phosphorylation followed by a slow decay phase.
The model also incorporates static regulation of MLCP
activity by the action of cyclic GMP (cGMP). This cyclic
nucleotide has been long recognized to be a relaxing agent for
smooth muscle cells, but how its main effector cGMP-
dependent protein kinase (cG kinase) achieves this activity is
still being investigated (Lincoln et al., 2001). Two parallel
mechanisms exist for relaxation by cGMP. The ﬁrst involves
the down-regulation of Ca21 channels (both plasma mem-
brane and intracellular), whereas the other involves direct
effects on MLCP or pathways that lead to MLCP down-
regulation (Cornwell and Lincoln, 1989; Lincoln et al., 2001).
FIGURE 4 Predictions of effects of myosin phosphatase regulatory
elements on MLC phosphorylation (MLC_P). (A) Simulation of MLC
phosphorylation as a function of the percent of MYTP prephosphorylated in
a model cell stimulated with 100 nM G protein-coupled receptor ligand.
MLC_P production increases with MYPT phosphorylation at 0 (thinnest
line), 25%, 50%, and 75% (thickest line) prephosphorylated enzyme. (B)
Simulation of MLC_P production in the presence and absence of CPI-17P
inhibitor generation, and stimulated MYPT phosphorylation: control (solid
line), no CPI-17 phosphorylation (dashed line), no additional MYTP1
phosphorylation (dotted line), and no additional MYPT phosphorylation or
CPI-17P (dot-dash line).
FIGURE 5 Ligand dependence of MLCP regulatory activities. Illustrated
are examples of simulated output of MLC_P production (solid lines), MYPT
phosphorylation (dashed lines), and CPI-17P-MLCP complex (dotted lines)
at (A) 1 nM, (B) 10 nM, and (C) 100 nM ligand.
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To test whether the modeled elements provide some level
of cGMP control, simulations were performed at different
cGMP concentrations ranging from 0.03 to 3 mM. First, the
cGMP concentration was changed in the absence of ligand
and the system allowed to equilibrate (;200 s). This resulted
in a new level of prephosphorylated MYTP1 subunit that was
entered as the new initial state. For example, at 3 mM cGMP,
the amount of phosphorylatedMYTP1 decreased to 3% of the
total. When the cGMP was lowered to 0.03 mM, the level of
prephosphorylated MYTP1 increased to 47%. As shown
earlier in Fig. 4, changing the basal level of MYPT1
phosphorylation dramatically affects the endpoint of MLC
phosphorylation. Thus, consistent with experimental data
(Lincoln et al., 2001), elevated cGMP results in a desensitized
state, whereas decreased cGMP results in sensitization.
Secondary regulation of MLCK activity
The current model does not include dynamic regulation of
MLCK activity through phosphorylation. It is known,
however, that MLCK activity may be modulated (in vitro)
through phosphorylation by kinases such as CaM-dependent
kinase II (CaMKII) (Stull et al., 1993; Ikebe and Reardon,
1990), mitogen-activated protein kinase (ERK-1) (Morrison
et al., 1996; Klemke et al., 1997), and PAK (Goeckeler et al.,
2000; Sanders et al., 1999). A 10–50% increase in MLCK
speciﬁc activity upon phosphorylation by ERK-1 in vitro has
been reported (Klemke et al., 1997; Morrison et al., 1996),
whereas phosphorylation by CaMKII (Ikebe and Reardon,
1990) or PAK-2 (Goeckeler et al., 2000; Sanders et al., 1999)
decreases the Ca21-CaM sensitivity of the kinase complex
with little change to its speciﬁc activity (Ikebe and Reardon,
1990). Kinetic analysis indicates that phosphorylated MLCK
bindsmore slowly to Ca21-CaM and dissociatesmore rapidly
when Ca21 is removed (Table 3) (Johnson et al., 1996;
Kasturi et al., 1993). Simulation parameters can be adjusted to
such changes in activation, but, unlike the regulatory subunit
of MLCP (MYPT), there is little data on the extent of MLCK
phosphorylation at speciﬁc sites in agonist-stimulated cells
(Stull et al., 1990).However, correlation of the desensitization
of MLCK activity by CaMKII phosphorylation of sites near
the CaM regulatory domain has been shown in cultured
smooth muscle cells and tissues (Tansey et al., 1992, 1994;
Stull et al., 1990). Fig. 6 provides examples of the predicted
effects of complete phosphorylation (100%) of MLCK by
CaMKII or PAK, phosphorylation byERK, and the combined
effect of both. In the case of CaMKII, reduced Ca21/CaM
sensitivity decreases peak MLC phosphorylation by at least
50%. As expected, ERK-1 phosphorylation of MLCK
potentiates MLC phosphorylation but fails to overcome the
inhibitory effects of phosphorylation byCaMKII. It should be
pointed out, however, that these predictions are at the
extremes because MLCK is rapidly dephosphorylated in
vitro by the PP1 and PP2A phosphatases (Nomura et al.,
1992). Thus, the timing and duration of MLCK phosphory-
lation with respect to other control elements will determine its
relevance in agonist-stimulated contractile events.
DISCUSSION
In this article, a comprehensive model of Ca21 signaling
through CaM and target proteins was tested in different
applications to biological problems on the downstream side of
the pathway. The ﬁrst problem is that of calmodulin buffering.
Most cellular CaM is bound to buffering molecules, some of
which must be located proximal to other CaM targets that are
activated by Ca21. To evaluate the CaM binding and Ca21-
release properties of the buffering molecules, the simulation
process proved useful in providing a plausible set of param-
eters for which a candidate protein, myosin Ic, was
identiﬁed and a putative buffering domain characterized.
Based upon the simulation results and estimates of myosin Ic
concentration in smooth muscle cells (Wilson et al., 2002),
less than 15% of the total CaM is sequestered by myosin Ic,
suggesting additional CaM buffering proteins are present.
There are two modes of CaM-releasing activity of CaM
buffering proteins. The difference in afﬁnity between Ca21-
dependent and Ca21-independent binding of CaM, as in
myosin Ic, allows buffering, but this property is not common
to all IQ motif-containing proteins (Bahler and Rhoads,
2002). In addition, phosphorylation of some of the neuron-
associated IQ-motif proteins, such as neurogranin and
neuromodulin, antagonizes CaM binding and releases CaM
to bind to other targets (Slemmon et al., 1996, 2000). CaM
buffering proteins with similar properties in nonneuronal
tissues remain to be identiﬁed. It is anticipated that some of
these will contain IQ domains similar in properties but not
necessarily primary structure to the myosin Ic domains.
Indeed, a recent report by Tran et al. (2003) demonstrates that
FIGURE 6 Predicted effects of MLCK prephosphorylation on MLC_P
production in agonist-stimulated cells. Models were modiﬁed to contain
phosphorylated MLCK with enhanced speciﬁc activity (ERK phosphory-
lation) or decreased Ca21-CaM sensitivity (CaMKII phosphorylation).
Simulations were done at 100 nM ligand (103 Kd) with no MLCK
phosphorylation (solid line), stoichiometric ERK phosphorylation (dashed
line), stoichiometric CaMKII phosphorylation (dotted lines), and a combi-
nation of both (dot-dash lines).
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the CaM-binding domain of endothelial cell nitric-oxide
synthase serves as an internal CaM buffer that sequesters
a signiﬁcant part (up to 25%) of the total cellular CaM in
certain endothelial cell lines.
The next problem investigated using the model and
predictive simulations was the complex regulation of myosin
phosphatase activity. This process involves multiple protein
phosphorylation events. In the control of MLCP phosphatase
activity, modeling efforts were focused on Rho kinase and
the CPI-17 inhibitor protein. Because of the ability of the
selective Rho kinase inhibitor, Y27632, to block Ca21 sensi-
tization of smooth muscle cells (Fu et al., 1998) and tissue
(Seko et al., 2003), this is probably the most ubiquitous
pathway for MLCP regulation. However, the relatively low
activity of RhoA-activated kinase suggests that constitutive
MLCP phosphorylation by Rho kinase and other known
MYPT kinases such as ZIP kinase and integrin-linked kinase
may contribute toward the initial set point of cellular MLCP
activity (unphosphorylated 1 phosphorylated enzyme).
Using simulations, this set point was found to be ;25%
phosphorylated MLCP.
In contrast to Rho kinase, the results from simulations
predict that CPI-17 plays a key role in the dynamic control
(i.e., during a Ca21 transient) ofMLCP activity. Activation of
PKC and phosphorylation of CPI-17 occurs within the same
time window as MLCK activation, whereas Rho kinase
activation is slower and serves to prolong MLC phosphory-
lation (Figs. 4 and 5). Although CPI-17 expression was
thought to be restricted to smooth muscle, recent work has
shown that this protein is expressed in some nonmuscle cells
such as platelets (Watanabe et al., 2001). Using selective PKC
and Rho-kinase inhibitors, the contribution of CPI-17 and
MYPT phosphorylation to MLC phosphorylation state has
been addressed. In platelets (Watanabe et al., 2001) or smooth
muscle cells (Kitazawa et al., 2003) inhibition of either
pathway reduced the MLC phosphorylation peak ;50%,
consistent with the current results predicted by the model and
simulation (Fig. 4B). In different types of smoothmuscle cells
(e.g., artery versus portal vein), similar experiments also
suggested that CPI-17 phosphorylation induced by agonist
stimulation may be more important for Ca21 sensitization in
cells that express high levels of CPI-17 compared to MLCP
(Woodsome et al., 2001; Kitazawa et al., 1999).
The last problem investigated the role of phosphorylation
of MLCK by other protein kinases. Stimulatory phosphor-
ylation of MLCK by MAP kinase (ERK-1) could be
important in certain nonmuscle cell types (Klemke et al.,
1997), but the model and simulation data indicate that
phosphorylation of MLCK by ERK-1 may not reverse the
down-regulation of Ca21 signaling caused by stoichiometric
CaMKII or PAK-1 phosphorylation. Thus, in the current
model for a smooth muscle cell, the simulation results are
consistent with experimental data in smooth muscle tissues
where the inhibition of MAP kinases did not inﬂuence
contractility (Gorenne et al., 1998).
Shortcomings of simulation data
The primary limitation of the model and simulation results is
the lack of quantiﬁcation of MLCP expression and various
regulatory domain (MYPT) isoforms present. Some existing
data suggest that regulation of MLCP will differ depending
upon the composition of the complex. For example, adult
chicken gizzard does not contain the MYPT isoform that has
a cG kinase-binding domain and is resistant to relaxation by
cGMP (Ogut andBrozovich, 2000). In contrast, aorta contains
mostly the MYPT isoform that binds cG kinase and is very
sensitive to relaxation by cGMP (Ogut and Brozovich, 2000).
In some tissues, increases in cGMP levels also regulateMLCP
activity through the phosphorylation and inhibition of RhoA,
thus pushing the basal level of MYPT phosphorylation
downward and decreasing Ca21 sensitivity (Murthy et al.,
2003; Begum et al., 2000). Drugs such as sildenaﬁl citrate
(Viagra) that inhibit cGMP phosphodiesterases work through
this pathway in vivo (Turko et al., 1999). Thus, MYPT
isoform expression data as well as quantitative determination
of the amounts of phosphorylated MYPT and various phos-
phorylated MLCK species present in a given tissue will allow
more accurate modeling of contractility in speciﬁc smooth
muscle tissues.
The Virtual Cell Portal is provided by the National Resource for Cell
Analysis and Modeling supported by National Institutes of Health grant
5P41RR013186.
REFERENCES
Bahler, M., and A. Rhoads. 2002. Calmodulin signaling via the IQ motif.
FEBS Lett. 513:107–113.
Begum, N., N. Duddy, O. Sandu, J. Reinzie, and L. Ragolia. 2000.
Regulation of myosin-bound protein phosphatase by insulin in vas-
cular smooth muscle cells: evaluation of the role of Rho kinase
and phosphatidylinositol-3-kinase-dependent signaling pathways. Mol.
Endocrinol. 14:1365–1376.
Blomquist, A., G. Schworer, H. Schablowski, A. Psoma, M. Lehnen, K. H.
Jakobs, and U. Rumenapp. 2000. Identiﬁcation and characterization of
a novel Rho-speciﬁc guanine nucleotide exchange factor. Biochem. J.
352:319–325.
Borman, M. A., J. A. MacDonald, A. Murany, D. J. Hartshorne, and T. A.
J. Haystead. 2002. Smooth muscle myosin phosphatase-associated kinase
induces Ca21 sensitization via myosin phosphatase inhibition. J. Biol.
Chem. 277:23441–23446.
Broustas, C. G., N. Grammatikakis, M. Eto, P. Dent, D. L. Brautigan, and
U. Kasid. 2002. Phosphorylation of the myosin-binding subunit of
myosin phosphatase by Raf-1 and inhibition of phosphatase activity.
J. Biol. Chem. 277:3053–3059.
Collins, K., J. R. Sellers, and P. Matsudaira. 1990. Calmodulin dissociation
regulates brush border myosin I (110-kD-calmodulin) mechanochemical
activity in vitro. J. Cell Biol. 110:1137–1147.
Coluccio, L. M. 1997. Myosin I. Am. J. Physiol. 273:C347–C359.
Cornwell, T. L., and T. M. Lincoln. 1989. Regulation of intracellular Ca21
levels in cultured vascular smooth muscle cells. Reduction of Ca21 by
atriopeptin and 8-bromo-cyclic GMP is mediated by cyclic GMP-
dependent protein kinase. J. Biol. Chem. 264:1146–1155.
Feng, J., M. Ito, K. Ichikawa, N. Isaka, M. Nishikawa, D. J. Hartshorne,
and T. Nakano. 1999a. Inhibitory phosphorylation site for
Calmodulin Signaling Model 1423
Biophysical Journal 87(3) 1417–1425
Rho-associated kinase on smooth muscle myosin phosphatase. J. Biol.
Chem. 274:37385–37390.
Feng, J., M. Ito, Y. Kureishi, K. Ichikawa, M. Amano, N. Isaka, K. Okawa,
A. Iwamatsu, K. Kaibuchi, D. J. Hartshorne, and T. Nakano. 1999b.
Rho-associated kinase of chicken gizzard smooth muscle. J. Biol. Chem.
274:3744–3752.
Fink, C. C., B. Slepchenko, and L. M. Loew. 1999. Determination of time-
dependent inositol-1,4,5-trisphosphate concentrations during calcium
release in a smooth muscle cell. Biophys. J. 77:617–628.
Fink, C. C., B. M. Slepchenko, I. I. Moraru, J. Watras, J. C. Schaff, and
L. M. Loew. 2000. An image-based model of calcium waves in
differentiated neuroblastoma cells. Biophys. J. 79:163–183.
Francis, S. H., B. D. Noblett, B. W. Todd, J. N. Wells, and J. D. Corbin.
1988. Relaxation of vascular and tracheal smooth muscle by cyclic
nucleotide analogs that preferentially activate puriﬁed cGMP-dependent
protein kinase. Mol. Pharmacol. 34:506–517.
Fu, X., M. C. Gong, T. Jia, A. V. Somlyo, and A. P. Somlyo. 1998. The
effects of the Rho-kinase inhibitor Y-27632 on arachidonic acid-,
GTPgammaS-, and phorbol ester-induced Ca21-sensitization of smooth
muscle. FEBS Lett. 440:183–187.
Gillespie, P. G., and J. L. Cyr. 2002. Calmodulin binding to recombinant
myosin-1c and myosin-1c IQ peptides. BMC Biochem. 3:31.
Goeckeler, Z. M., R. A. Masaracchia, Q. Zeng, T.-L. Chew, P. A.
Gallagher, and R. B. Wysolmerski. 2000. Phosphorylation of myosin
light chain kinase by p21-activated kinase PAK2. J. Biol. Chem. 275:
18366–18374.
Gorenne, I., X. Su, and R. S. Moreland. 1998. Inhibition of p42 and p44
MAP kinase does not alter smooth muscle contraction in swine carotid
artery. Am. J. Physiol. 275:H131–H138.
Hayashi, Y., S. Senba, M. Yazawa, D. L. Brautigan, and M. Eto. 2001.
Deﬁning the structural determinants and a potential mechanism for
inhibition of myosin phosphatase by the protein kinase C-potentiated
inhibitor protein of 17 kDa. J. Biol. Chem. 276:39858–39863.
Ikebe, M., and S. Reardon. 1990. Phosphorylation of smooth muscle
myosin light chain kinase by smooth muscle Ca21/calmodulin-
dependent multifunctional protein kinase. J. Biol. Chem. 265:8975–8978.
Johnson, J. D., C. Snyder, M. P. Walsh, and M. Flynn. 1996. Effects of
myosin light chain kinase and peptides on Ca21 exchange with the
N- and C-terminal Ca21 binding sites of calmodulin. J. Biol. Chem.
271:761–767.
Kasturi, R., C. Vasulka, and J. D. Johnson. 1993. Ca21, caldesmon, and
myosin light chain kinase exchange with calmodulin. J. Biol. Chem.
268:7958–7964.
Kawano, Y., Y. Fukata, N. Oshiro, M. Amano, T. Nakamura, M. Ito, F.
Matsumura, M. Inagaki, and K. Kaibuchi. 1999. Phosphorylation of
myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in
vivo. J. Cell Biol. 147:1023–1037.
Kiss, E., A. Murany, C. Csortos, P. Gergely, M. Ito, D. J. Hartshorne, and
F. Erdodi. 2002. Integrin-linked kinase phosphorylates the myosin
phosphatase target subunit at the inhibitory site in platelet cytoskeleton.
Biochem. J. 365:79–87.
Kitazawa, T., M. Eto, T. P. Woodsome, and D. L. Brautigan. 2000.
Agonists trigger G protein-mediated activation of the CPI-17 inhibitor
phosphoprotein of myosin light chain phosphatase to enhance vascular
smooth muscle contractility. J. Biol. Chem. 275:9897–9900.
Kitazawa, T., M. Eto, T. P. Woodsome, and M. Khalequzzaman. 2003.
Phosphorylation of the myosin phosphatase targeting subunit and CPI-17
during Ca21 sensitization in rabbit smooth muscle. J. Physiol. 546:
879–889.
Kitazawa, T., N. Takizawa, M. Ikebe, and M. Eto. 1999. Reconstitution of
protein kinase C-induced contractile Ca21 sensitization in triton X-100-
demembranated rabbit arterial smooth muscle. J. Physiol. 520:139–152.
Klemke, R. L., S. Cai, A. L. Giannini, P. J. Gallagher, P. de Lanerolle, and
D. A. Cheresh. 1997. Regulation of cell motility by mitogen-activated
protein kinase. J. Cell Biol. 137:481–492.
Lincoln, T. M., N. Dey, and H. Sellak. 2001. Invited review: cGMP-
dependent protein kinase signaling mechanisms in smooth muscle: from
the regulation of tone to gene expression. J. Appl. Physiol. 91:
1421–1430.
Loew, L. M., and J. C. Schaff. 2001. The Virtual Cell: a software
environment for computational cell biology. Trends Biotechnol. 19:
401–406.
Lukas, T. J. 2004. A signal transduction pathway prototype I: from agonist
to cellular endpoint. Biophys. J. 87:1406–1416.
Lukas, T. J., S. Mirzoeva, U. Slomczynska, and D. M. Watterson. 1999.
Identiﬁcation of novel classes of protein kinase inhibitors using
combinatorial peptide chemistry based on functional genomics knowl-
edge. J. Med. Chem. 42:910–919.
Morrison, D. L., J. S. Sanghera, J. Stewart, C. Sutherland, M. P. Walsh, and
S. L. Pelech. 1996. Phosphorylation and activation of smooth muscle
myosin light chain kinase by MAP kinase and cyclin-dependent kinase-1.
Biochem. Cell Biol. 74:549–557.
Murthy, K. S., H. Zhou, J. R. Grider, and G. M. Makhlouf. 2003. Inhibition
of sustained smooth muscle contraction by PKA and PKG preferentially
mediated by phosphorylation of RhoA. Am. J. Physiol. Gastrointest.
Liver Physiol. 284:G1006–G1016.
Nakamura, M., K. Ichikawa, M. Ito, B. Yamamori, T. Okinada, N. Isaka, Y.
Yoshida, S. Fujita, and T. Nakano. 1999. Effects of the phosphorylation
of myosin phosphatase by cyclic GMP-dependent protein kinase. Cell.
Signal. 11:671–676.
Nomura, M., J. T. Stull, K. E. Kamm, and M. C. Mumby. 1992. Site-
speciﬁc dephosphorylation of smooth muscle myosin light chain kinase
by protein phosphatases 1 and 2A. Biochemistry. 31:11915–11920.
Ogut, O., and F. V. Brozovich. 2000. Determinants of the contractile
properties in the embryonic chicken gizzard and aorta. Am. J. Physiol.
279:C1722–C1732.
Sanders, L. C., F. Matsumura, G. M. Bokoch, and P. de Lanerolle. 1999.
Inhibition of myosin light chain kinase by p21-activated kinase. Science.
283:2083–2085.
Sandu, O. A., M. Ito, and N. Begum. 2001. Selected contribution: insulin
utilizes NO/cGMP pathway to activate myosin phosphatase via Rho
inhibition in vascular smooth muscle. J. Appl. Physiol. 91:1475–1482.
Seko, T., M. Ito, Y. Kureishi, R. Okamoto, N. Moriki, K. Onishi, N. Isaka,
D. J. Hartshorne, and T. Nakano. 2003. Activation of RhoA and
inhibition of myosin phosphatase as important components in hyperten-
sion in vascular smooth muscle. Circ. Res. 92:411–418.
Senba, S., M. Eto, and M. Yazawa. 1999. Identiﬁcation of trimeric myosin
phosphatase (PP1M) as a target for a novel PKC-potentiated protein
phosphatase-1 inhibitory protein (CPI17) in porcine aorta smooth
muscle. J. Biochem. (Tokyo). 125:354–362.
Slemmon, J. R., B. Feng, and J. A. Erhardt. 2000. Small proteins that
modulate calmodulin-dependent signal transduction: effects of PEP-19,
neuromodulin, and neurogranin on enzyme activation and cellular
homeostasis. Mol. Neurobiol. 22:99–113.
Slemmon, J. R., J. I. Morgan, S. M. Fullerton, W. Danho, B. S. Hilbush,
and T. M. Wengenack. 1996. Camstatins are peptide antagonists of
calmodulin based upon a conserved structural motif in PEP-19,
neurogranin, and neuromodulin. J. Biol. Chem. 271:15911–15917.
Slepchenko, B. M., J. C. Schaff, J. H. Carson, and L. M. Loew. 2002.
Computational cell biology: spatiotemporal simulation of cellular events.
Annu. Rev. Biophys. Biomol. Struct. 31:423–441.
Slepchenko, B. M., J. C. Schaff, I. Macara, and L. M. Loew. 2003.
Quantitative cell biology with the Virtual Cell. Trends Cell Biol. 13:
570–576.
Smith, J. A., R. B. Reed, S. H. Francis, K. Grimes, and J. D. Corbin. 2000.
Distinguishing the roles of the two different cGMP-binding sites for
modulating phosphorylation of exogenous substrate (heterophosphor-
ylation) and autophosphorylation of cGMP-dependent protein kinase.
J. Biol. Chem. 275:154–158.
Somlyo, A. P., and A. V. Somlyo. 2000. Signal transduction by G-proteins,
rho-kinase and protein phosphatase to smooth muscle and non-muscle
myosin II. J. Physiol. 522:177–185.
1424 Lukas
Biophysical Journal 87(3) 1417–1425
Stull, J. T., L. C. Hsu, M. G. Tansey, and K. E. Kamm. 1990. Myosin light
chain kinase phosphorylation in tracheal smooth muscle. J. Biol. Chem.
265:16683–16690.
Stull, J. T., M. G. Tansey, D. C. Tang, R. A. Word, and K. E. Kamm. 1993.
Phosphorylation of myosin light chain kinase: a cellular mechanism for
Ca21 desensitization. Mol. Cell. Biochem. 127–128:229–237.
Surks, H. K., N. Mochizuki, Y. Kasai, S. P. Georgescu, K. M. Tang, M. Ito,
T. M. Lincoln, and M. E. Mendelsohn. 1999. Regulation of myosin
phosphatase by a speciﬁc interaction with cGMP-dependent protein
kinase 1a. Science. 286:1583–1587.
Takizawa, N., Y. Koga, and M. Ikebe. 2002a. Phosphorylation of CPI17
and myosin binding subunit of type 1 protein phosphatase by p21-
activated kinase. Biochem. Biophys. Res. Commun. 297:773–778.
Takizawa, N., N. Niiro, and M. Ikebe. 2002b. Dephosphorylation of the
two regulatory components of myosin phosphatase, MBS and CPI17.
FEBS Lett. 515:127–132.
Tansey, M. G., K. Luby-Phelps, K. E. Kamm, and J. T. Stull. 1994.
Ca(21)-dependent phosphorylation of myosin light chain kinase
decreases the Ca21 sensitivity of light chain phosphorylation within
smooth muscle cells. J. Biol. Chem. 269:9912–9920.
Tansey, M. G., R. A. Word, H. Hidaka, H. A. Singer, C. M. Schworer,
K. E. Kamm, and J. T. Stull. 1992. Phosphorylation of myosin light
chain kinase by the multifunctional calmodulin-dependent protein kinase
II in smooth muscle cells. J. Biol. Chem. 267:12511–12516.
Taylor, D. A., and J. T. Stull. 1988. Calcium dependence of myosin light
chain phosphorylation in smooth muscle cells. J. Biol. Chem. 263:
14456–14462.
Tran, Q. K., D. J. Black, and A. Persechini. 2003. Intracellular coupling via
limiting calmodulin. J. Biol. Chem. 278:24247–24250.
Turko, I. V., S. A. Ballard, S. H. Francis, and J. D. Corbin. 1999. Inhibition
of cyclic GMP-binding cyclic GMP-speciﬁc phosphodiesterase (Type 5)
by sildenaﬁl and related compounds. Mol. Pharmacol. 56:124–130.
Vorherr, T., P. James, J. Krebs, A. Enyedi, D. J. McCormick, J. T.
Penniston, and E. Carafoli. 1990. Interaction of calmodulin with the
calmodulin binding domain of the plasma membrane Ca21 pump.
Biochemistry. 29:355–365.
Watanabe, Y., M. Ito, Y. Kataoka, H. Wada, M. Koyama, J. Feng, H.
Shiku, and M. Nishikawa. 2001. Protein kinase C-catalyzed phosphor-
ylation of an inhibitory phosphoprotein of myosin phosphatase is
involved in human platelet secretion. Blood. 97:3798–3805.
Wilson, D. P., C. Sutherland, and M. P. Walsh. 2002. Ca21 activation of
smooth muscle contraction: evidence for the involvement of calmodulin
that is bound to the triton insoluble fraction even in the absence of Ca21.
J. Biol. Chem. 277:2186–2192.
Woodsome, T. P., M. Eto, A. Everett, D. L. Brautigan, and T. Kitazawa.
2001. Expression of CPI-17 and myosin phosphatase correlates with
Ca(21) sensitivity of protein kinase C-induced contraction in rabbit
smooth muscle. J. Physiol. 535:553–564.
Zhu, T., K. Beckingham, and M. Ikebe. 1998. High afﬁnity Ca21 binding
sites of calmodulin are critical for the regulation of myosin Ibeta motor
function. J. Biol. Chem. 273:20481–20486.
Zimmermann, B., A. V. Somlyo, G. C. Ellis-Davies, J. H. Kaplan, and A. P.
Somlyo. 1995. Kinetics of prephosphorylation reactions and myosin light
chain phosphorylation in smooth muscle. Flash photolysis studies with
caged calcium and caged ATP. J. Biol. Chem. 270:23966–23974.
Calmodulin Signaling Model 1425
Biophysical Journal 87(3) 1417–1425
